Title : Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.

Pub. Date : 2015 Jan

PMID : 25121488






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OUTCOMES: Therapy in patients with steroid dependence and CNI-dependent steroid resistance led to significantly reduced relapse rates (respective mean difference 2.7 relapses/year and 2.2 relapses/year, corresponding to a decrease in relapses by 81.8 and 71.0%; both P < 0.0001). Steroids calcineurin binding protein 1 Homo sapiens
2 Remission was longer in patients with steroid dependence compared with CNI-dependent steroid resistance (median 16 versus 10 months; P < 0.0001). Steroids calcineurin binding protein 1 Homo sapiens
3 Prior response to cyclophosphamide predicted a lower risk of relapse in the former (hazard ratio, HR 0.56; P = 0.045); patients with initial resistance and CNI-dependent steroid resistance had increased risk of relapse (HR 2.66; P = 0.042). Steroids calcineurin binding protein 1 Homo sapiens
4 CONCLUSIONS: Therapy with rituximab is effective and safe in reducing relapse rates and need for immunosuppressive medications in patients with steroid-dependent and CNI-dependent steroid-resistant nephrotic syndrome. Steroids calcineurin binding protein 1 Homo sapiens